Search Results

World-renowned physicians and researchers from City of Hope®, one of the largest cancer research and treatment organizations in the United States, will present new data and offer expert perspectives on leading-edge cancer research and treatments in development at the 2024 ASCO Annual Meeting.

Propanc Biopharma, Inc. today announced that a certificate of grant for the Company’s “composition of proenzymes for cancer treatment,” patent was received from the European Patent Office.

23andMe Holding Co., a leading genetic health and biopharmaceutical company, and the Colorectal Cancer Alliance, the largest nonprofit organization dedicated to ending colorectal cancer, announced a collaboration to help advance research on colorectal cancer in the Black/African American community.

BeiGene, Ltd., a global oncology company, announced that the European Commission has approved tislelizumab as a treatment for non-small cell lung cancer across three indications, including first- and second-line use.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the European Commission (EC) has approved a label extension for XTANDI™ (enzalutamide) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage-radiotherapy.

Florida Cancer Specialists & Research Institute, LLC is proud to announce an initiative aimed at revolutionizing cancer care – the introduction of designated FCS Disease Site Teams for late-phase research and the subsequent formation of the FCS Disease Site Committee.

Susan G. Komen®, the world’s leading breast cancer organization, announced $10.05 million in research grants that aim to improve patient lives through better treatments for metastatic disease and advancements in precision medicine.

Mainz Biomed N.V. will be organizing the HALLO DOC! event, informing about colorectal cancer, cutting-edge research, new treatment modalities, and holistic therapeutic approaches.